Results 111 to 120 of about 86,485 (257)
Updated COVID‐19 Vaccines and Health Outcomes in Patients With Autoimmune Rheumatic Conditions
Arthritis &Rheumatology, EarlyView.Objective We aimed to assess the association between COVID‐19 vaccination status and COVID‐19‐related hospital admissions, need for mechanical ventilation or extracorporeal membrane oxygenation (ECMO), and death in people with autoimmune rheumatic conditions. Methods We conducted a retrospective cohort study using National Clinical Cohort Collaborative
Lesley E. Jackson +127 more
wiley +1 more source
Cancer in Systemic Sclerosis: Clinical Associations and Prognostic Impact From the EUSTAR Registry
Arthritis &Rheumatology, EarlyView.Objective Cancer represents a major cause of death in systemic sclerosis (SSc). Established risk factors are limited to specific subsets, particularly early diffuse anti‐RNA polymerase III (POLR3)–positive disease, needing further exploration. Methods We performed a nested case‐control study within the European Scleroderma Trials and Research group ...
Antonio Tonutti +52 more
wiley +1 more source
Human Monocytic Models Reveal Genotype‐Dependent Inflammatory Programs in VEXAS Syndrome
Arthritis &Rheumatology, Accepted Article.Objectives VEXAS syndrome is a severe X‐linked autoinflammatory disorder caused by somatic mutations in ubiquitin‐like modifier activating enzyme 1 (UBA1), with clinical outcomes that vary by UBA1 genotype. We aimed to elucidate genotype‐specific inflammatory programs and identify potential therapeutic targets.
Kana Higashitani +10 more
wiley +1 more source
Tocilizumab in the treatment of rheumatoid arthritis and beyond
, 2014 Anjali Shetty,1 Rebekah Hanson,1 Peter Korsten,2 Munir Shawagfeh,3 Shiva Arami,1 Suncica Volkov,1 Olga Vila1 William Swedler,1 Abdel Naser Shunaigat,4 Sameer Smadi,4 Ray Sawaqed,5 David Perkins,1 Shiva Shahrara,1 Nadera J Sweiss11Department of ...
Shunaigat AN +13 more
core
Efficacy, safety and cost‐effectiveness of CAR‐T therapy
British Journal of Clinical Pharmacology, EarlyView.CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher +7 more
wiley +1 more source
Investigating the Short-Term Changes of the Electrocardiogram Indicators During Hospitalization in Patients With COVID-19 Following the Use of Tocilizumab. [PDF]
Ann Noninvasive ElectrocardiolTocilizumab, an IL‐6 inhibitor used in severe COVID‐19, may have cardiovascular effects. This study examined short‐term electrocardiographic (ECG) changes 24 h before versus 24 h after tocilizumab injection in PCR‐positive COVID‐19 patients. Retrospective study of 33 ICU‐admitted COVID‐19 patients (36.4% male, age 37–79 years). ECG parameters including
Zahedi M, Houshmand G, Hosseini T.
europepmc +2 more sources
Regulatory harmonization: Evolution, globalization and future directions
British Journal of Clinical Pharmacology, EarlyView.Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm +2 more
wiley +1 more source
High Mortality Rate in Severe COVID-19 Despite Tocilizumab Administration: A Case Series
JKS (Jurnal Kedokteran Syiah Kuala)Introduction: Tocilizumab is a potential therapeutic agent for modulating cytokine storms, a known cause of multiorgan failure and mortality in severe COVID-19.
Cokorda Agung Wahyu Purnamasidhi +4 more
doaj +1 more source
Implementation and use of risk minimization control tools in the EU: A multistakeholder survey
British Journal of Clinical Pharmacology, EarlyView.Aims This study characterized stakeholders' experiences with national implementation of risk minimization control tools (RMCTs), such as healthcare professional qualification, healthcare facility accreditation and medical intervention prior to treatment initiation, for eight medicinal products across eight European Union countries. Methods We conducted
Sharon C. M. Essink +21 more
wiley +1 more source
Lack of tocilizumab effect on mortality in COVID19 patients
, 2020 Off-label tocilizumab use in COVID-19 patients reflects concern for cytokine release syndrome. Comparison of matched COVID-19 pneumonia patients found elevated IL-6 levels correlated with mortality that did not change with tocilizumab administration ...
arias, sixto +10 more
core +1 more source